Incremental cost effectiveness of proton pump inhibitors for the prevention of non-steroidal anti-inflammatory drug ulcers: a pharmacoeconomic analysis linked to a case-control study

Table 4 Expected monthly costs (based on defined daily dose) and cost effectiveness for different PPIs at 2007 price levels [10]

Drug	Defined daily dose^a	Monthly costs (November 2006)	Cost effectiveness ratio (lower and upper limit)^b
Generic omeprazole	20 mg	€ 11.30	4,907 (2,813 to 6,290)
Lansoprazole (Prezal^®)	30 mg	€ 29.71	26,545 (24,327 to 28,051)
Omeprazole (Losec^®)	20 mg	€ 29.85	26,709 (24,491 to 28,217)
Rabeprazole (Pariet^®)	20 mg	€ 31.75	28,943 (26,711 to 30,463)
Pantaprazole (Pantozol^®)	40 mg	€ 36.41	34,420 (32,157 to 35,971)
Esomeprazole (Nexium^®)	30 mg	€ 39.37	37,899 (35,617 to 39,470)

^aThe daily dosing schedule on which the cost effectiveness ratio is based, may not always reflect the actual dosages prescribed in clinical practice; ^bcost effectiveness is expressed as costs (€) per serious NSAID ulcer complication prevented: lower and upper limit are the results of the sensitivity analyses.
NSAID, non-steroidal anti-inflammatory drug.

ISSN: 1478-6362